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CONTEXT—Circulating fatty acid synthase (FASN) is a bio-
marker of metabolically demanding human diseases. The aim of
this study was to determine whether circulating FASN could be
a biomarker of overnutrition-induced metabolic stress and insu-
lin resistance in common metabolic disorders.
RESEARCH DESIGN AND METHODS—Circulating FASN
was evaluated in two cross-sectional studies in association with
insulin sensitivity and in four longitudinal studies investigating
the effect of diet- and surgery-induced weight loss, physical
training, and adipose tissue expansion using peroxisome prolif-
erator–activated receptor agonist rosiglitazone on circulating
FASN.
RESULTS—Age- and BMI-adjusted FASN concentrations were
signiﬁcantly increased in association with obesity-induced insu-
lin resistance in two independent cohorts. Both visceral and
subcutaneous FASN expression and protein levels correlated
inversely with extracellular circulating FASN (P  0.63; P 
0.0001), suggesting that circulating FASN is linked to depletion of
intracellular FASN. Improved insulin sensitivity induced by ther-
apeutic strategies that decreased fat mass (diet induced, surgery
induced, or physical training) all led to decreased FASN levels in
blood (P values between 0.02 and 0.04). To discriminate whether
this was an effect related to insulin sensitization, we also
investigated the effects of rosiglitazone. Rosiglitazone did not
lead to signiﬁcant changes in circulating FASN concentration.
CONCLUSIONS—Our results suggest that circulating FASN is a
biomarker of overnutrition-induced insulin resistance that could
provide diagnostic and prognostic advantages by providing in-
sights on the individualized metabolic stress. Diabetes 59:
1506–1511, 2010
T
he main problem of obesity is not as much the
degree of expansion of the adipose tissue as the
increased susceptibility to cardiometabolic risk.
As obesity becomes more prevalent, a funda-
mental diagnostic challenge is to identify among the obese
population individuals whose obesity causes more meta-
bolic stress and who, consequently, are more likely to
develop type 2 diabetes and cardiovascular diseases. Iden-
tiﬁcation of these individuals has enormous obvious ther-
apeutic and economic implications. Whereas there is
general agreement that epidemiologically obesity poses
a cardiometabolic risk, it is also true that not all obese
individuals develop cardiometabolic complications.
Conversely, it is also true that some individuals develop
metabolic complications inappropriately severe for
their degree of obesity. This suggests that the fat mass
per se may not be the best predictor and that a marker
that could indicate the metabolic stress posed by a
speciﬁc degree of obesity may be particularly useful.
However, there are no good early predictor markers of
the metabolic risk posed by obesity. Thus, new thera-
peutic targets and biomarkers useful for diagnostic and
prevention purposes, ideally pathogenically linked, are
urgently needed.
Accumulating evidence suggests that lipid metabolism is
as important, if not more, to diabetes as carbohydrate
metabolism. The anabolic effects of insulin are not limited
to facilitating glucose uptake. In fact, insulin is the most
lipogenic hormone and exerts important effects on protein
metabolism. Insulin is an important regulator of fatty acid
synthase (FASN), a key enzyme in de novo lipogenesis.
Coordinately with acetyl CoA carboxylase (ACC), FASN
determines the lipogenic ﬂux from malonyl CoA into
palmitate (1,2). Expression of the FASN gene is primarily
regulated by hormonal and nutritional signals (3,4), and
insulin particularly not only increases the rate of FASN
gene transcription in murine cell lines and in primary
human adipocytes but also increases human FASN gene
expression and FASN enzymatic activity (5–7). Con-
versely, FASN is markedly inactivated under conditions of
insulin resistance. Therefore, we hypothesized that a
marker related to the de novo lipogenic pathway, and
more speciﬁcally FASN, might provide some insights on
the level of impairment of insulin sensitivity and metabolic
stress.
In support of FASN being a potential marker for meta-
bolic stress, there is evidence that FASN, an intracellular
protein, can also be detected at increased levels in the
extracellular space of human cancer cells (8–10). It has
been suggested that when FASN is excessively accumu-
lated beyond the metabolic needs of the cellular system,
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stressed tumor cell (10). In fact, altered energy metabo-
lism, and especially dysfunction of glucose/lipid metabo-
lism, is an early hallmark that contributes to the
pathophysiology of several human malignancies (3,11–13).
Current evidence indicates that extracellular/circulating
FASN occurs exclusively during invasive/metastatic can-
cer progression.
In support of our hypothesis, there is evidence that
increased extracellular/circulating FASN levels are detect-
able in human diseases typically associated with insufﬁ-
ciently met increased energy demands (e.g., hypoxia or
increased nutrient demand in rapidly growing carcinoma
cells). Because AMP-activated protein kinase (AMPK) is
essential to ensure intracellular energy homeostasis (14–
17), we recently assessed whether activation of phosphor-
ylation (activation) status of AMPK, known to spare de
novo lipogenesis, may directly facilitate the release of
FASN in response to cellular energy depletion. AMPK
activation not only decreased de novo lipogenesis but also
facilitated the release of extracellular FASN in human
breast cancer cells (18). These results support the hypoth-
esis that FASN release is an active and controlled process
regulated and facilitated by AMPK activation in the con-
text of energy depletion.
Obesity-induced insulin resistance is characterized by
the relative inability to take up glucose, leading to intra-
cellular glucopenia associated with increased intracellular
lipid deposition in adipose tissue. Insulin resistance also
impairs the process of de novo lipogenesis in adipose
tissue. We hypothesized that in the context of insulin
resistance, energy depletion caused by intracellular gluco-
penia, activation of AMPK, and impaired lipogenesis may
be coupled with increased secretion of FASN, resulting in
increased circulating FASN levels. As such, circulating
FASN could become a surrogate bona ﬁde marker of the
degree of metabolic compromise caused by a certain
degree of obesity.
RESEARCH DESIGN AND METHODS
To test the main hypothesis, we evaluated circulating FASN in different
cohorts of subjects, summarized in Fig. 1. The cross-sectional association of
circulating FASN with insulin sensitivity was studied in two independent
cohorts and the relationship with adipose tissue FASN gene expression in
one cohort. Furthermore, we evaluated the effects of diet-induced weight loss
(cohort 1), exercise improvement of insulin sensitivity (cohort 2), bariatric
surgery–induced weight loss (cohort 3), and rosiglitazone-associated improve-
ment of insulin sensitivity (cohort 4).
All study protocols have been approved by the ethics committee of the
participant institutions. All participants gave written informed consent before
taking part in the study.
Cross-sectional studies
Cohort 1. One hundred and thirty-ﬁve Caucasian men were consecutively
recruited in an ongoing study dealing with nonclassical cardiovascular risk
factors in northern Spain. Recruiting criteria and analysis of insulin sensitivity
are described as supplemental material in an online appendix (http://
diabetes.diabetesjournals.org/cgi/content/full/db09-1756/DC1).
Cohort 2. Paired samples of visceral and subcutaneous adipose tissue were
obtained from 98 consecutively recruited Caucasian men (n  49) and women
(n  49) who underwent open abdominal surgery for gastric banding,
cholecystectomy, weight reduction surgery, abdominal injuries, or explorative
laparotomy. After explantation, samples of visceral and subcutaneous adipose
tissue were immediately frozen in liquid nitrogen. Human visceral and subcuta-
neous adipose tissue FASN gene expression was measured by quantitative
real-time RT-PCR as previously described (19). Age ranged from 17 to 79 years
and BMI from 21.7 to 61.5 kg/m
2. The study included 62 patients with impaired
glucose tolerance or type 2 diabetes and 36 controls with normal glucose
tolerance. All subjects had a stable weight, deﬁned as the absence of ﬂuctuations
of 2% of body weight for at least 3 months before surgery. Patients with
malignant diseases or any acute or chronic inﬂammatory disease, as determined
by a leukocyte count of 7,000 Gpt/l, C-reactive protein levels of 50 mg/l, or
clinical signs of infection, were excluded from the study.
Studies of changing insulin action. The sample size and power calculations
for the studies were based on our previous work (20), in which 12 subjects
would enable the detection of 10% difference in insulin sensitivity index (Si)
with a 90% power at the 1% level.
Cohort 1: diet-induced weight loss. Fifteen Caucasian obese volunteers
(12 female and three male, with an age range between 19 and 60 years)
attending the Endocrinology Department at the University Clinic of Navarra
were recruited. For more details, please see the online appendix.
Cohort 2. Eight healthy male subjects participated in a prospective random-
ized 12-week intensive-training intervention study. Inclusion criteria are
shown in Appendix 1. In brief, each training session included 20 min of biking
or running, 45 min of circle training, and 20 min of warming up and cooling
down periods. All subjects completed a graded bicycle test to volitional
exhaustion and had maximal oxygen uptake measured with an automated
open-circuit gas-analysis system at baseline. The highest oxygen uptake per
minute reached was deﬁned as the maximal oxygen uptake (VO2max), and
subjects subsequently trained at their individual submaximal heart rate using
heart rate monitors. At baseline and after 4, 8, and 12 weeks of training, blood
samples were obtained in the fasting state.
Cohort 3. Ten women participated in a prospective weight loss study before
and 12 months after gastric sleeve resection. The baseline BMI was 48.3  4.2
kg/m
2, and the BMI 12 months after bariatric surgery was 37.2  5.9 kg/m
2.
Inclusion criteria can be found in the online appendix.
Cohort 4. We conducted a parallel-group randomized and controlled trial to
evaluate the effects of rosiglitazone and physical exercise on endothelial
function in patients with coronary artery disease and pre-diabetes over a
6-month period. Further information can be found in the online appendix.
• Cross-sectional studies
– Association of circulating FASN 
with insulin sensitivity in 2 
cohorts (n=135 and n=98)
– Association with fatty acid 
synthase gene expression in 1 
cohort (n=98).
• Longitudinal studies
Study of the changes in circulating FASN 
induced by:
• Diet-induced weight loss. Cohort 1 
(n=15).
• Exercise improvement of insulin 
sensitivity. Cohort 2 (n=8).
• Bariatric surgery-induced weight 
loss. Cohort 3 (n=10).
• Rosiglitazone improvement of 
insulin sensitivity. Cohort 4 (n=16). 
FIG. 1. Summary of the studies performed on circulating FASN levels.
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were measured in serum without additives by a sandwich enzyme immuno-
assay (FAS-Detect ELISA; FASgen, Baltimore, MD) according to the manufac-
turer’s instructions. The within- and between-run coefﬁcients of variation
were 10%, and the detection limit was 3.22 ng/ml. FASN concentrations were
also measured by Western blot (see below) in 10 subjects (ﬁve insulin
resistant and ﬁve insulin sensitive). Circulating FASN was also measured by
Western blot in 10 subjects (ﬁve insulin resistant and ﬁve insulin sensitive).
The remaining analytical methods and statistical analyses are described in the
online appendix.
RESULTS
Serum FASN concentration is inversely associated
with insulin sensitivity. Cross-sectional studies revealed
that age- and BMI-adjusted serum FASN concentrations
were inversely associated with insulin sensitivity in two
independent cohorts of subjects. In the ﬁrst cohort, the
association was signiﬁcant in all subjects as a whole (r 
0.20; P  0.02), especially in subjects with altered
glucose tolerance (r  0.44; P  0.004) (Fig. 2A). In the
second cohort, the association was highly signiﬁcant (r 
0.60; P  0.0001) (Fig. 2B). As hypothesized, the highest
levels of FASN concentrations in serum were observed in
obese subjects with altered glucose tolerance (online
appendix Table 1). Also in support of our hypothesis,
FASN gene expression in visceral and subcutaneous adi-
pose tissue correlated negatively with extracellular FASN
in the obese glucose-intolerant group of subjects (r 
0.44, P  0.01, and r  0.31, P  0.05, respectively). As
expected, these results were especially robust in the
extreme of the spectrum corresponding with obese sub-
jects who had developed type 2 diabetes (r  0.63; P 
0.0001) (Fig. 3A). The relevance of these ﬁndings was
conﬁrmed with the protein levels in serum (Fig. 3B) and
adipose tissue (not shown). This indicates that under
metabolic stress and in association with insulin resistance,
intracellular levels of FASN may decrease by the com-
bined effects of decreased biosynthesis coupled with in-
creased secretion of FASN protein, leading to increased
plasma levels.
Studies of changing insulin action. From our results
indicating that insulin resistance, a state where de novo
lipogenesis and FASN biosynthesis is severely compro-
mised, is associated with increased FASN levels in plasma,
we hypothesized that strategies aiming at improving insu-
lin sensitivity systemically should reverse this effect. To
address this, we evaluated four different strategies known
to improve insulin sensitivity but with a different impact
on lipid biosynthesis: 1) lifestyle changes (diet-induced
weight loss and physical training–induced improvement of
insulin sensitivity), 2) surgery-induced weight loss, and 3)
pharmacological intervention. An alternative AMPK-inde-
pendent strategy was to promote safe fat accumulation
and lipogenesis mediated by rosiglitazone in vivo (cohort
4), which we predicted would not result in decreased
FASN secretion.
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FIG. 2. A: Linear association between circulating FASN concentration and insulin sensitivity according to glucose tolerance status (upper panel:
normal glucose tolerance; lower panel: altered glucose tolerance). Although the absolute value of circulating FASN is reported, the statistical analysis
was performed using its log-transformed value. B: Linear association between log circulating FASN concentration and insulin sensitivity in all subjects
(solid line with 95% CI) and according to glucose tolerance status (dotted lines). The association was also signiﬁcant in each subgroup separately (r 
0.43, P  0.01, in subjects with normal glucose tolerance [NGT] and r  0.39, P  0.02, in subjects with type 2 diabetes).
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using a diet-induced weight loss strategy (characteristics
of the subjects shown in online appendix Table 2) led to
signiﬁcantly decreased circulating FASN concentration in
those with altered glucose tolerance (i.e., initially elevated
FASN plasma levels) and remained essentially unchanged
in subjects with normal glucose tolerance (Fig. 4A)i n
whom circulating FASN levels initially were not affected.
Exercise also reduced signiﬁcantly circulating FASN
concentrations in young men without any comorbidities
(Fig. 4B). Similarly, surgery-induced weight loss by
gastric sleeve resection also led to a signiﬁcant lowering
of serum FASN concentration (Fig. 4C). These experi-
mental paradigms clearly indicate that under conditions
where there is an improvement in insulin sensitivity
associated with increased bioenergetic efﬁciency or
decreased intracellular FASN, there is a decrease in
FASN levels in serum.
As an alternative, we used rosiglitazone in vivo (cohort
4), an AMPK-independent insulin sensitizer that binds and
activates nuclear receptor peroxisome proliferator–acti-
vated receptor  and can be predominantly considered
anabolic, activating lipogenesis and promoting fat deposi-
tion. Under these conditions, FASN accumulated in adi-
pose tissue, but this was not associated with a parallel
increase in FASN in plasma (12.2  3 ng/ml vs. 11.4  4
ng/ml; P  0.5) in vivo.
DISCUSSION
To the best of our knowledge, we have described the
following for the ﬁrst time: 1) A relationship between
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FIG. 3. A: Linear association between log circulating FASN concentration and FASN gene expression in visceral adipose tissue in subjects with
type 2 diabetes. B: Western blot showing the fragment recognized by the antibody used in the enzyme-linked immunosorbent assay in
insulin-resistant (lanes 1–5) and insulin-sensitive (lanes 6–10) subjects. Previous experience indicates that FASN is an ordered cellular response
of a living cell that actively extrudes excess intracellular FASN molecules from the cell (reference 10). The extracellular FASN molecules are
present in various immunoreactive forms and show different expression patterns. In serum of breast cancer patients, the FASN is a small
molecule similar to the form in breast cancer cell lysate. We here substantiate that a 150 kDa fragment is preferentially detected in serum from
subjects with insulin resistance.
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FASN. 2) Circulating FASN was inversely associated with
adipose tissue FASN expression. This supports the hy-
pothesis that circulating extracellular FASN levels in-
crease in parallel with the metabolic stress of the cells, as
indicated by their decreased amounts of intracellular
FASN levels. 3) Decreased concentration of circulating
FASN is a good correlate of improvement in insulin action
and metabolic control, as evidenced during subtle lifestyle
interventions or surgery-induced weight loss. And 4)
FASN plasma levels work as a marker of insulin sensitivity
only in the context of metabolic stress, given that rosigli-
tazone, which promotes lipid biosynthesis and storage, did
not lead to changes in circulating FASN.
We cannot exclude the possibility that the liver could
also contribute to circulating FASN. In fact, weight loss
patients typically improve in metabolic function quickly
after massive weight loss, but liver disease caused by
obesity is slower to reverse.
Our results indicate that states of overnutrition-induced
insulin resistance and decreased de novo lipogenesis are
associated with increased FASN in serum. Situations that
improve insulin sensitivity either through decreasing sub-
strate availability or optimizing fat deposition are associated
with normalization of FASN in serum. In this respect, FASN
levels in plasma of obese individuals could be considered a
marker of metabolic failure in the context of overnutrition-
induced insulin resistance and metabolic stress.
The fact that FASN can be secreted actively from the
cell in response to AMPK pharmacological activation
(18) suggest that this could be a mechanism of physio-
logical relevance in the context of nutritional depriva-
tion. It is known that AMPK activation decreases
lipogenesis de novo through its well-known effect of
phosphorylating and inactivating ACC. Our results sup-
port the hypothesis that secretion of FASN could be a
regulated process aiming to eliminate unnecessary
FASN activity under conditions where lipogenesis is
spared. It could be speculated that since FASN is a
fundamental determinant of malonyl CoA levels, it
would make biological sense to have a coupled mecha-
nism associated with activation of AMPK-induced inac-
tivation of ACC that prevented the collapse of malonyl
CoA and its subsequent effects promoting uncontrolled
fatty acid oxidation. In our opinion, in situations known
to induce energy depletion and AMPK activation (fast-
ing, weight loss, and physical exercise), the increased
release and turnover of FASN may provide a mechanism
to extrude this enzyme when is no longer needed under
conditions of depleted energy stores.
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FIG. 4. A: Change in log circulating FASN concentration after weight loss in all subjects (left panel) and according to glucose tolerance status
(right panels). B: Change in circulating FASN in healthy lean young men after 3-month physical training–induced improvement of insulin action.
*P  0.05 compared with baseline. C: Change in circulating FASN after surgery-induced weight loss. **P  0.01.
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FASN displays any signaling capacity. In our opinion, this
is quite unlikely because the 150 kDa NH2-terminal
fragment would likely not have FASN activity because
several essential domains would be missing: ACP, TE, KR,
and ER and probably the second half of the DH domain
(21). The fragment likely is still capable of dimerization
through the KS domains (E. Brignole, personal communi-
cation). Furthermore, the fragment cannot carry sub-
strates (acyl or malonyl) because the ACP is absent. The
fragment probably resembles a 142 kDa fragment that
results from limited proteolysis of FASN with kallikrein
(22) and splits the DH domain in half. Interestingly, plasma
kallikrein is increased in diabetic patients (23).
Earlier studies demonstrated that cultured cancer cells
can excrete immunoreactive FASN into the extracellular
space in a time-dependent and hormone-independent man-
ner (8–10). The current view is that circulating FASN can
be detected solely in the serum of cancer patients. Here,
we demonstrate that increased levels of extracellular/
circulating FASN are also a common feature associated
with hypernutrition-induced metabolic disturbances. Fur-
thermore, our data suggest that measurements of FASN
may have the added value of providing a measure of
metabolic failure associated with a certain degree of
obesity. We can envisage that FASN markers could have a
better predictive value about metabolic stress and compli-
cations than BMI alone.
In summary, here we provide data indicating that FASN
can be actively secreted under condition of overnutrition-
induced metabolic stress and that FASN per se may be not
only a diagnostic marker but also prognostic of obesity-
associated metabolic complications. Thus, we hypothesize
that FASN markers could be used to identify and prioritise
obese patients for aggressive therapeutic intervention. We
believe our data are interesting enough to warrant large-scale
studies.
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